



20th Annual Oncology Research & Education Day

Co-Chairs: Ana Lohmann MD. PhD. and Vanessa Dumeaux PhD.

Thursday, June 13, 2024 8:30 AM – 5:30 PM

(Breakfast starts at 7:45 am)

Best Western Lamplighter Inn, Crystal Ballroom, Regency Room, Chelsea Room, and Atrium
591 Wellington Rd. S., London, Ontario, N6C4R3

AGENDA

Overall Learning Objectives:

By the end of this program, participants will be able to:

1. To review contributions from different oncology disciplines, including medical oncology, radiation oncology, surgery, and medical biophysics, to a comprehensive cancer treatment approach;
2. Discuss and assess cutting-edge research in oncology, including novel methodologies for studying cancer at the cellular level and the implications for treatment resistance and patient care;
3. Appraise research findings and demonstrate how collaboration bridge clinical and basic science research in oncology.

7:45 – 9:00	REGISTRATION AND OPENING REMARKS <i>Atrium & Crystal Ballroom</i>
 7:45	Registration and Breakfast Please register and enjoy a light breakfast while networking with colleagues.
8:30	Welcome and Opening Remarks Ana Lohmann MD. PhD. and Vanessa Dumeaux, PhD. - Conference Co-Chairs Michael Ott MD. FRCS(C) - Chair/Chief, Department of Oncology Kirk Baines – Philanthropist & Founder of the Baines Centre for Translational Cancer Research
9:00 – 9:30	ONCOLOGY TALKS <i>Crystal Ballroom</i>
9:00	Experimental Oncology: Translating Science into Survival Division of Experimental Oncology – Saman Maleki PhD. Learning Objectives: 1. To describe how to transform immune cold tumors to immune hot via induction of DNA repair damage in tumor cells; 2. The describe the role of gut microbiome in anti-tumor immune response; 3. To describe how modifying the gut microbiome to increase the effectiveness of immunotherapy in patients.
9:15	Is Anthracycline Chemotherapy Essential in the Treatment of Women with Breast Cancer? Division of Medical Oncology - Danilo Giffoni MD. FRCP(C). Learning Objectives: 1. Compare efficacy between anthracycline vs. non-anthracycline chemotherapy in early breast cancer; 2. Introduce treatment strategies for high-risk breast cancer; 3. Present cardiotoxicity risks induced by anthracycline.
9:30 – 10:10	MORNING ORAL PRESENTATIONS Judges: Drs. Gabriel DiMattia, Charles Gawad, and Michael Ott <i>Crystal Ballroom</i>
9:30	1. Exploring the Role of Gut Microbiota on Immunologically Active Neuroblastoma Tumours – Hasti Gholami, MSc. Candidate
9:40	2. Mice deficient in RanBP9 and p53 display increased tumourigenesis – Brianna Gongga-Cave, PhD Candidate
9:50	3. Body Composition and Melanoma Outcomes in Patients on Immunotherapy or Targeted Therapy – an analysis from Canadian Melanoma Research Network - Sanji Ali, MO PGY5
10:00	4. Exploring the mutational landscape of pure ductal carcinoma in situ and its association with disease progression and response to radiotherapy – Noor Rizvi, MSc. Candidate
10:10 – 11:45	POSTER AND NETWORKING SESSION (Odd Numbers) <i>Regency and Chelsea Conference Rooms & Atrium</i>
 10:10 - 11:45	Poster Viewing and Judging (Regency and Chelsea Conference Rooms) Please enjoy refreshments and light snack (Atrium)

11:45 – 12:45	<p style="text-align: center;">KEYNOTE LECTURE – Crystal Ballroom “Dissecting Tissue Genomes at Single-Cell Resolution” Charles Gawad MD. PhD.</p> <p>Objectives: Define somatic mutation and explain how those genetic changes can contribute to diseases; Describe the tools used for single-cell sequencing and the unique information obtained from this approach compared to standard tissue-level sequencing; Define single-cell multiomics and discuss the insights into cancer biology that can be gained by studying the genome and transcriptome of the same cancer cell.</p>
12:45 – 1:45 	<p style="text-align: center;">LUNCH Crystal Ballroom & Atrium</p>
1:45 – 2:30	<p style="text-align: center;">ONCOLOGY TALKS</p>
1:45	<p>Introducing a New Paradigm with Real-Time Adaptive Radiotherapy in London Division of Medical Biophysics – Jason Vickress PhD. MCCPM. Learning Objectives: Define Adaptive Radiotherapy in the current clinical context; 2. Examine new technologies enabling Real-Time Adaptive Radiotherapy in London; 3. Formulate future research projects for Real-Time Adaptive Radiotherapy.</p>
2:00	<p>Adapting to Changing Ideals and Evolving Essentials in Radiation Oncology Division of Radiation Oncology – Joelle Helou MD. FRCPC. Learning Objectives: 1. To review recent paradigm changes in metastatic cancer; 2. To integrate advanced technology in the changing landscape of systemic treatments and precision medicine; 3. To integrate patient values and preferences in our decision-making</p>
2:15	<p>Modern Approaches in Translational Breast Cancer Research Division of Surgery – Armen Parsyan MD. PhD. FRCSC. Learning Objectives: 1. To provide an overview describing some cutting-edge methodologies in translational breast cancer research; 2. To describe how these technologies are utilized in translational breast cancer research; 3. At the end of this session, participants will be able to describe how newly identified target molecules can potentially be utilized in breast cancer management in the future.</p>
2:30 – 3:10	<p style="text-align: center;">AFTERNOON ORAL PRESENTATIONS Judges: Drs. Gabriel DiMattia, Charles Gawad, and Michael Ott Crystal Ballroom</p>
2:30	<p>5. Impact of macrophages on immune checkpoint inhibitor response in DNA mismatch repair-deficient neuroblastoma tumours – Megan Hong, PhD Candidate</p>
2:40	<p>6. DNA methylation profiles define new epigenetic-based pancreatic ductal adenocarcinoma subtypes – Joana Ribeiro Pinto, PhD Candidate</p>
2:50	<p>7. Analyzing the effect of neoadjuvant stereotactic ablative radiotherapy (SABR) on pancreatic tumour perfusion using computed tomography perfusion (CTP) – Jin-Young Bang, MSc. Candidate</p>
3:00	<p>8. Exploring Principles of the Interplay Between Tumour-Initiating Cells and the Tumour Microenvironment in Glioblastoma”– Alan Cieslukowski, MSc. Candidate</p>
3:10 – 4:45 	<p style="text-align: center;">POSTER & NETWORKING SESSION – (Even Numbers) Regency & Chelsey Conference Rooms & Atrium</p>
3:10 – 4:45	<p>Poster Viewing and Judging (Regency and Chelsea Conference Rooms) Please enjoy refreshments and light snack (Atrium)</p>
4:45 – 5:30	<p style="text-align: center;">Award Ceremony</p>
4:45	<p>Presentation of Awards Michael Ott - <i>Department of Oncology, Excellence in Academic and Teaching Awards (5)</i> Morgan Black - <i>Denise Power Cancer Research Staff Award of Excellence</i> Ana Lohmann and Vanessa Dumeaux - <i>Oral and Poster Presentation Awards</i></p>
5:30	<p>Concluding Remarks and Adjournment Ana Lohmann and Vanessa Dumeaux</p>

*25% of this program is dedicated to participant interaction.

* This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by Continuing Professional Development, Schulich School of Medicine & Dentistry, Western University. You may claim a maximum of **3.75 hours** (credits are automatically calculated).

*This program has received an educational grant or in-kind support from; Silver Sponsors: AbbVie, Agendia, AstraZeneca, Astella, Eisai, EMD Serono, GSK, Ipsen, Janssen, Jazz Pharmaceuticals, Knight Therapeutics, Lilly, Merck, Novartis, Pfizer, Roche. Bronze Sponsors: BeiGene, Gilead, Takeda